TRELEGY ELLIPTA Drug Patent Profile

Which patents cover Trelegy Ellipta, and what generic alternatives are available?

Trelegy Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-nine patent family members in forty-nine countries.

The generic ingredient in TRELEGY ELLIPTA is fluticasone furoate; umeclidinium bromide; vilanterol trifenatate. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fluticasone furoate; umeclidinium bromide; vilanterol trifenatate profile page.

DrugPatentWatch^® Generic Entry Outlook for Trelegy Ellipta

Trelegy Ellipta was eligible for patent challenges on May 10, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 29, 2030. This may change due to patent challenges or generic licensing.

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRELEGY ELLIPTA

International Patents:	199
US Patents:	6
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRELEGY ELLIPTA

Paragraph IV (Patent) Challenges for TRELEGY ELLIPTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRELEGY ELLIPTA	Powder for Inhalation	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	200 mcg/62.5 mcg/ 25 mcg	209482	1	2026-03-19
TRELEGY ELLIPTA	Powder for Inhalation	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	100 mcg/62.5 mcg/ 25 mcg	209482	1	2025-11-26

US Patents and Regulatory Information for TRELEGY ELLIPTA

TRELEGY ELLIPTA is protected by six US patents.

This potential generic entry date is based on patent 9,750,726.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes	11,090,294
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020		RX	Yes	Yes	7,488,827		Y	Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes	7,488,827		Y	Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020		RX	Yes	Yes	9,750,726		Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes	9,750,726		Y

International Patents for TRELEGY ELLIPTA

When does loss-of-exclusivity occur for TRELEGY ELLIPTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Norway

Peru

Poland

Portugal

Russian Federation

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Turkey

Ukraine

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRELEGY ELLIPTA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2010326798
Australia	2014204459
Australia	2016262698
Australia	2017238392
Australia	2018282427

Supplementary Protection Certificates for TRELEGY ELLIPTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1740177	2014/057	Ireland		PRODUCT NAME: UMECLIDINIUM BROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140428
1740177	58/2014	Austria		PRODUCT NAME: UMECLIDINIUMBROMID; REGISTRATION NO/DATE: EU/1/14/922 (MITTEILUNG) 20140430
1740177	PA2014038,C1740177	Lithuania		PRODUCT NAME: UMEKLIDINO BROMIDAS; REGISTRATION NO/DATE: EU/1/14/922 20140428
1740177	1490060-9	Sweden		MARKETING AUTHORIZATION NUMBER AND DATE OF GRANT/NOTIFICATION: EU/1/14/922, 2014-04-30; PERIOD OF VALIDITY (FROM - UNTIL): 20250428 - 20240429
1740177	300694	Netherlands		PRODUCT NAME: UMECLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140430

TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol) investment scenario and patent-and-exclusivity fundamentals

Last updated: August 1, 2026

Executive summary

• Commercial core: Trelegy Ellipta is the leading US-brand triple therapy for COPD (ICS/LAMA/LABA) and is used as a high-share maintenance inhaler. Key investment inputs are US exclusivity timing, patent estate strength around device/formulation/methods, and timeline risk from ANDA/Paragraph IV generic entry and coordinated payer pressure.
• IP posture (what investors underwrite): Exclusivity and patents on inhaled formulation and dosing determine generic leverage points. The investment case is strongest when (1) the patent estate covers multiple claim “angles” (formulation, methods of treatment, and delivery-device related features where applicable) and (2) FDA approvals for COPD generics face limited “design-around” space.
• Risk model (what can break the case): Patent-expiration-driven generic entry for COPD and competitive pressure from other triple therapies (including rival fixed-dose combinations) plus LTD (lung disease) guideline movement toward alternative regimens can compress unit share and price even before full generic launch.
• Actionable framing: Underwrite returns with a timeline that separately models (a) US patent expiration, (b) exclusivity end, and (c) likely generic launch window as constrained by Paragraph IV litigation and settlement timing.

What patents protect Trelegy Ellipta (fluticasone furoate umeclidinium vilanterol)?

Quick answer Trelegy’s patent protection in the US typically spans three buckets investors track: (1) inhaled formulation and particle/mixture characteristics of the three actives in the fixed-dose combination, (2) delivery-device/inhalation performance related compositions or dosing regimens, and (3) methods of treatment for COPD and related endpoints using the fixed triple regimen. Actual enforceable coverage depends on the specific Orange Book-listed patents for the marketed strengths and dosage forms.

Which drug is Trelegy’s “reference product” in the patent record?

• Drug components: fluticasone furoate (ICS), umeclidinium (LAMA), vilanterol (LABA)
• Product: Trelegy Ellipta inhalation powder
• Key investment concept: most generic leverage comes from whether an ANDA can be approved under bioequivalence while carving around formulation, method-of-use, and device/dosing claims that remain enforceable when eligibility is assessed.

How many Orange Book patents typically cover Trelegy COPD strengths?

Investors evaluate:

• Number of Orange Book entries tied to each listed strength
• Remaining unexpired claims count per family (formulation vs method vs composition-of-matter)
• Whether multiple patents expire at different times, creating staggered risk rather than a single cliff

Where does the strongest IP typically concentrate in fixed-dose triple inhalers?

• Combination formulation: particle engineering, ratios, and stability under device storage conditions
• Dosing regimen: method-of-treatment claim framing tied to COPD maintenance and symptom control
• Process/manufacturing: sometimes constrained by “know-how” and process validation, but the enforceability basis is claim language rather than manufacturing capability

Note: Trelegy patent granularity is product- and strength-specific; enforceability must be read claim-by-claim against the Orange Book listings for the exact marketed inhalation strengths.

---

When does Trelegy Ellipta lose exclusivity in the US?

Quick answer US exclusivity and patent timelines create a two-layer barrier to generic entry: statutory exclusivity (where applicable) and last-expiring Orange Book patent that can block ANDA commercial marketing even when FDA approval is granted.

What exclusivity types matter for inhaled triple therapies?

Investors generally separate:

• Regulatory exclusivity: tied to New Chemical Entity (NCE) or other exclusivity frameworks (if applicable to component status at approval)
• Patent exclusivity: last-expiring Orange Book patent(s) enforce marketing prohibition
• Biosimilar risk: not applicable to Trelegy since it is a small molecule triple inhaler

What is the practical generic-entry timing window?

A typical investment mapping:

1. First unexpired barrier: earliest Orange Book patent expiration that removes the “marketing block”
2. Paragraph IV litigation: can extend effective exclusivity by triggering stay/settlement terms
3. Launch sequencing: label work, device and inhaler usability alignment, payer contracting, and channel stocking

---

What patent expiration dates drive the Trelegy generic launch scenario?

Quick answer The decisive dates are the last-expiring US patents listed in the FDA Orange Book for Trelegy Ellipta inhalation powder. The generic launch window starts when no longer blocked by enforceable patents or exclusivity and after any litigation/settlement delay.

How do staggered expirations change investor expectations?

• Early expiration of a subset of patents can allow partial design-around or motivate challengers, but commercial entry still requires clearing the last listed blocking patent.
• If multiple families expire far apart, expected revenue compression may occur in phases, not as a single event.

What do investors model in a “cliff vs slope” scenario?

• Cliff: a single last-expiring blocking patent date with no meaningful settlements
• Slope: multiple expirations create staged risk, with challengers filing early and launching later

---

How many Paragraph IV challenges exist for Trelegy Ellipta, and which companies filed?

Quick answer To evaluate Paragraph IV risk, investors rely on the FDA’s ANDA Paragraph IV litigation disclosures and court dockets. The investment case depends on (1) number of challenges, (2) asserted patents, and (3) settlement structure.

What to look for in Paragraph IV case selection

• Whether challengers assert design-around strategies (different formulations or process routes)
• Whether asserted patents are mainly formulation or method-of-use
• Whether cases settle with launch-date covenants or other reverse-payment structures

What settlement terms typically matter financially

• A settlement can shift the effective entry date by months to years relative to bare patent expiration.
• Investors track whether the covenant covers generic labeling, exclusivity carve-outs, and launch trigger conditions.

---

What is the Orange Book status of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)?

Quick answer Orange Book status determines the “hard” marketing barrier: listed patents and their expiration dates for each strength/formulation.

What investors need from Orange Book listings

• Patent numbers
• Patent types (drug substance, drug product, method-of-use)
• Statutory expiration or adjusted expiration dates
• Relation to specific Trelegy strengths (e.g., 100/62.5/25 mcg versus other strengths)

How does Orange Book listing density influence investment risk?

• Dense and overlapping coverage generally increases litigation leverage for the brand.
• Thin coverage increases the probability of successful early carve-outs and earlier generic entry.

---

How strong is the patent estate for Trelegy Ellipta: formulation, device, and method-of-use?

Quick answer The strength of Trelegy’s patent estate is assessed by the number of enforceable families and the claim types most vulnerable to generic “paper approval but marketing-blocked-by-patent.”

Formulation patents: why they matter

• Fixed-dose inhalation products hinge on mixture and physical characteristics that affect delivered dose and stability.
• A generic ANDA must meet release and delivery specifications, but formulation patents can block marketing.

Method-of-use patents: why they matter

• If claims focus on using the specific triple regimen for COPD management endpoints, challengers need a labeling or claim carve-out to avoid infringement.

Device-related considerations

• Trelegy uses the Ellipta platform for dry powder inhalation. Device design can create an IP border, but infringement typically depends on claim scope rather than device platform alone.

---

What generic entry risks exist for Trelegy Ellipta, and how could challengers design around?

Quick answer Generic risk concentrates in ANDA pathway capability and infringement avoidance. The main question is not FDA approval alone, but whether the challenger can market without infringing active Orange Book blocking patents.

Generic risk drivers

• Whether the ANDA can certify using paragraph IV against multiple patents or whether it must use carve-outs
• Whether the challenger’s proposed formulation/dosing produces infringement or a viable non-infringing variant
• Whether the challengers can obtain a favorable settlement that delays launch

Commercial “entry readiness” barriers

Even with legal clearance, generics face:

• Device usability and patient handling training
• Formulary contracts and pharmacist substitution behavior
• COPD guideline alignment and prescriber inertia

---

How does Trelegy Ellipta compare with other triple therapy inhalers on IP and risk?

Quick answer Compared with other ICS/LAMA/LABA fixed-dose inhalers, Trelegy’s investment profile depends on (1) whether its patent estate extends longer, (2) payer share concentration, and (3) whether competitors have similar durability or are approaching their own expiration.

What to compare across brands

• Orange Book entry counts and last expiration dates
• Strength-specific patent cliffs
• Litigation and settlement history
• Channel share volatility around major guideline updates

Where competitors can steal share even without generic entry

• Superior patient outcomes data in narrow subpopulations
• Lower out-of-pocket costs via manufacturer programs and payer tiering
• Better dosing convenience perceptions

---

What FDA regulatory status does Trelegy Ellipta have, and how does it affect exclusivity?

Quick answer Trelegy is approved as a fixed-dose maintenance inhaler for COPD; regulatory status affects eligibility for certain exclusivity mechanisms and dictates how generic ANDAs would be evaluated (including required bioequivalence and product-specific testing).

What investors track in FDA records

• Label changes that expand or narrow indicated use
• Supplements that can trigger new patent listings or create new “patent thickets”
• Expiration and exclusivity linkages between labeling and Orange Book patents

---

What patent litigation affects Trelegy Ellipta, and what is the expected outcome distribution?

Quick answer Litigation affects the effective generic entry date through:

• Findings of invalidity or non-infringement (speeding entry)
• Injunctions or sustained infringement (delaying entry)
• Settlements that set launch covenants

How litigation outcomes map to revenue risk

• Brand win: delays generic marketing, preserving pricing power
• Partial win/settlement: sets a negotiated launch date, often with limited early entry
• Generic win: can trigger faster erosion, especially if multiple challengers coordinate entry

---

What licensing or settlement agreements matter for Trelegy Ellipta?

Quick answer For fixed-dose inhalers, brand licensing and litigation settlements are typically the mechanisms that define the actual market launch horizon versus the raw patent expiration calendar.

Settlement terms that change valuation

• Launch date covenants (earliest practical date)
• Limits on authorized strengths and formulation versions
• Labeling restrictions tied to method-of-use carve-outs

---

What manufacturing and IP barriers affect generic competitors for Trelegy?

Quick answer Beyond legal barriers, challengers face operational hurdles that can delay entry and weaken commercial impact even if patents fall.

Key execution risks

• Dry powder inhalation formulation and moisture sensitivity control
• Device-to-dose consistency and delivered dose reproducibility
• Supply chain scaling for inhaled products and combination actives

---

Revenue exposure: what portion of COPD spending could be at risk if Trelegy loses patent protection?

Quick answer Revenue sensitivity is driven by the “time-to-erosion” after first eligible generic entry. Investors underwrite:

• share velocity (how quickly payers shift)
• price compression depth
• channel mix (mail vs retail, formulary vs non-formulary)

What drives post-entry erosion speed

• Payer formulary position of the brand
• Patient switching costs and prescriber behavior
• Number of generic entrants and competitive intensity

---

Investment scenario: base case, bull case, bear case for Trelegy’s patent-and-competition outlook

Base case (patent durability + normal competition)

• Generic entry occurs no earlier than the last blocking patent expiration plus any litigation timing.
• Brand maintains premium formulary placement through ongoing patient continuity.
• Erosion begins near the effective launch window; pricing compression is controlled by contract dynamics.

Bull case (strong litigation posture and delayed effective entry)

• Court outcomes and/or settlements push generic marketing later than the raw calendar.
• Competitors’ triple therapy share growth plateaus due to formulary constraints and patient continuity.
• Net revenue decline is slower than expected due to limited generic penetration at first entry.

Bear case (earlier-than-expected effective entry)

• One or more key patents are invalidated or found non-infringing, creating a shorter path to launch.
• Multiple ANDA challengers launch within a short window, driving rapid price compression.
• Guideline changes or payer behavior accelerates switching.

---

Key Takeaways

• Trelegy’s investment fundamentals hinge on the Orange Book patent estate and Paragraph IV litigation/settlement calendar, not just regulatory approval.
• Investors should model generic risk as a two-stage barrier: (1) patent/exception clearing for marketing and (2) payer and patient switching behavior after launch.
• IP strength is typically highest in formulation and method-of-use claim areas that constrain design-around and labeling carve-outs.
• Competitive risk can erode share even without immediate generic entry through formulary tiering, outcomes evidence, and out-of-pocket economics.

---

FAQs

1) What is the Orange Book “blocking patent” concept for Trelegy Ellipta?

The blocking patent is the last unexpired FDA-listed patent tied to Trelegy’s marketed inhalation strengths that prevents generic commercial marketing even after FDA approval of an ANDA.

2) Do method-of-use patents block generic ANDA marketing for Trelegy?

They can, depending on claim scope and whether the generic’s proposed labeling induces infringement or violates label carve-outs.

3) Can a generic receive FDA approval but still not launch Trelegy in the US?

Yes. FDA approval can occur under ANDA pathways while patent infringement status or court/settlement terms still block commercial marketing.

4) Does Trelegy face biosimilar-type risks?

No. Trelegy is a small-molecule triple therapy inhaler, so the biosimilar framework does not apply.

5) What non-patent factors accelerate Trelegy revenue erosion after generic entry?

Formulary contracting, payer rebate structures, patient switching, number of entrants, and pharmacy substitution behavior.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Orange Book database).
2. FDA. ANDA Paragraph IV Certifications and Disclosures (as published via FDA information systems). U.S. Food and Drug Administration.
3. FDA. Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) prescribing information and related FDA labeling history. U.S. Food and Drug Administration.
4. FDA. Drugs@FDA: Trelegy Ellipta (application and approval history). U.S. Food and Drug Administration.